

## Recommendation for Promoting Antimicrobial Resistance (AMR) Countermeasures in the Basic Policy on Economic and Fiscal Management and Reform 2022

May 30, 2022  
AMR Alliance Japan

### **Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2022**

**Promote countermeasures for antimicrobial resistance (AMR) with a One Health approach from perspectives including economic security and serve as a global leader in strengthening preparedness against the threat of infectious disease.**

AMR infections are a threat that is equivalent to Coronavirus Disease 2019 (COVID-19) and discussions based on their tentative status as a priority infectious disease are accelerating. To advance measures for managing AMR-related risks, AMR Alliance Japan recommends the Basic Policy on Economic and Fiscal Management and Reform 2022 include the above.

Starting in 2016, the Basic Policy on Economic and Fiscal Management and Reform has clearly outlined the importance of AMR control every year, with mention of “strengthening efforts to promote AMR control and expanding systems for research, testing, and treatment.”

As described in “Promoting Antimicrobial Resistance (AMR) Countermeasures in the Basic Policy on Economic and Fiscal Management and Reform 2022 Recommendation Background” (attached separately), measures to combat AMR are advancing in Japan and around the world. As president of the upcoming G7 conference in 2023, it is important for us to fulfill our responsibilities in the global community based on an understanding that infectious disease control cannot be fully accomplished by Japan alone.

About AMR Alliance Japan: Established in November 2018, AMR Alliance Japan is an independent platform for multi-stakeholder discussion on AMR control. As of May 2022, its members include MSD K.K., the Children and Healthcare Project, Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., the Japanese Society of Antimicrobials for Animals, Nippon Becton Dickinson Co., Ltd., the Japan Medical Association, the Japanese Society for Medical Mycology, the Japanese Society of Pharmaceutical Health Care and Sciences, the Japanese Society of Chemotherapy, the Japanese Society for Infection Prevention and Control, the Japanese Association for Infectious Diseases, the Japanese Society for Pediatric Infectious Diseases, the Japan Pharmaceutical Manufacturers Association, the Japanese Society of Therapeutic Drug Monitoring, the Japan Society of Hospital Pharmacists, the Pharmaceutical Society of Japan, the Japan Pharmaceutical Association, the Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, and Pfizer Japan Inc. Health and Global Policy Institute (HGPI) serves as its secretariat.